Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HMPL 004

Drug Profile

HMPL 004

Alternative Names: HMPL-004

Latest Information Update: 01 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer Hutchison MediPharma; Nutrition Science Partners
  • Class Anti-inflammatories; Antiulcers
  • Mechanism of Action Interleukin 1 beta inhibitors; Interleukin 6 inhibitors; NF-kappa B inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease
  • Phase I Ulcerative colitis

Most Recent Events

  • 20 Mar 2018 Phase-I clinical trials in Crohn's disease (In volunteers) in Australia (PO)(NCT03597971)
  • 20 Mar 2018 Phase-I clinical trials in Ulcerative colitis (In volunteers) in Australia (PO)(NCT03597971)
  • 02 Aug 2016 Hutchinson MediPharma announces intention to submit IND application to FDA in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top